CD19&CD22 bispecific CAR-T cells is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Beijing Tongren Hospital (2) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1). Registered phases: Phase 2 and Phase 1/2. Conditions studied include B-Cell Lymphoblastic Leukemia/Lymphoma; Large B-Cell Lymphoma (LBCL); B-cell Acute Lymphoblastic Leukemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia (ClinicalTrials.gov ↗) B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma |
Phase 2 | Recruiting |
| NCT06735495 | CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors (ClinicalTrials.gov ↗) B-Cell Lymphoblastic Leukemia/Lymphoma |
Phase 1/2 | Recruiting |
| NCT07461831 | CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (ClinicalTrials.gov ↗) Large B-Cell Lymphoma (LBCL) |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| B-Cell Lymphoblastic Leukemia/Lymphoma | 1 |
| Large B-Cell Lymphoma (LBCL) | 1 |
| B-cell Acute Lymphoblastic Leukemia | 1 |
| B-cell Lymphoma | 1 |
| Diffuse Large B Cell Lymphoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Beijing Tongren Hospital | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Register | CD19&CD22 bispecific CAR-T cells trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CD19&CD22 bispecific CAR-T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CD19&CD22 bispecific CAR-T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.